Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Change in Receivables: 2023-2025

Historic Change in Receivables for Immunocore Holdings (IMCR) over the last 3 years, with Sep 2025 value amounting to $6.0 million.

  • Immunocore Holdings' Change in Receivables rose 173.22% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.6 million, marking a year-over-year decrease of 50.06%. This contributed to the annual value of $12.3 million for FY2024, which is 30.90% down from last year.
  • As of Q3 2025, Immunocore Holdings' Change in Receivables stood at $6.0 million, which was up 43.38% from $4.2 million recorded in Q2 2025.
  • Immunocore Holdings' Change in Receivables' 5-year high stood at $10.2 million during Q4 2023, with a 5-year trough of -$836,000 in Q1 2025.
  • Its 3-year average for Change in Receivables is $3.6 million, with a median of $3.6 million in 2023.
  • In the last 5 years, Immunocore Holdings' Change in Receivables skyrocketed by 365.39% in 2024 and then tumbled by 113.49% in 2025.
  • Immunocore Holdings' Change in Receivables (Quarterly) stood at $10.2 million in 2023, then slumped by 87.33% to $1.3 million in 2024, then soared by 173.22% to $6.0 million in 2025.
  • Its Change in Receivables was $6.0 million in Q3 2025, compared to $4.2 million in Q2 2025 and -$836,000 in Q1 2025.